版本:
中国

BRIEF-Cerecor reports topline data from a NIH sponsored proof-of-concept trial of CERC-501 in treatment-resistant depression

May 1 Cerecor Inc

* Cerecor reports encouraging topline data from a NIH sponsored proof-of-concept trial of Cerc-501 in treatment-resistant depression

* Cerecor Inc - CERC-501 generally well-tolerated with no serious adverse events reported and no discontinuations due to adverse events with CERC-501

* Clinically meaningful improvements observed at day 3 from proof-of-concept trial of CERC-501 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐